D
Diana Lake
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 53
Citations - 1396
Diana Lake is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 20, co-authored 47 publications receiving 1203 citations. Previous affiliations of Diana Lake include University of Chicago & Cornell University.
Papers
More filters
Journal ArticleDOI
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.
Gary A. Ulaner,Serge K. Lyashchenko,Christopher C. Riedl,Christopher C. Riedl,Shutian Ruan,Pat Zanzonico,Diana Lake,Komal Jhaveri,Komal Jhaveri,Brian M. Zeglis,Jason S. Lewis,Jason S. Lewis,Joseph A. O'Donoghue +12 more
TL;DR: This first-in-human study demonstrated safety, dosimetry, biodistribution, and successful HER2-targeted imaging with 89Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)– targeted imaging in patients with Her2-positive breast cancer.
Journal ArticleDOI
A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Maura N. Dickler,Hope S. Rugo,Carey A. Eberle,Edi Brogi,James F. Caravelli,Katherine S. Panageas,Jeff Boyd,Benjamin M. Yeh,Diana Lake,Chau T. Dang,Teresa Gilewski,Jacqueline Bromberg,Andrew D. Seidman,Gabriella D'Andrea,Mark M. Moasser,M. Melisko,John W. Park,Janet Dancey,Larry Norton,Clifford A. Hudis +19 more
TL;DR: The combination of erlotinib and bevacizumab was well-tolerated but had limited activity in unselected patients with previously treated MBC, and biomarkers are needed to identify those MBC patients likely to respond to anti-EGFR/HER1 plus anti-VEGF therapy.
Journal ArticleDOI
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Ethan Basch,Ethan Basch,Amylou C. Dueck,Lauren J. Rogak,Lori M. Minasian,William Kevin Kelly,Ann M. O'Mara,Andrea Denicoff,Drew K. Seisler,Pamela J. Atherton,Electra D. Paskett,Lisa A. Carey,Maura N. Dickler,Rebecca S. Heist,Andrew L. Himelstein,Hope S. Rugo,William M. Sikov,Mark A. Socinski,Alan P. Venook,Douglas Weckstein,Diana Lake,David D. Biggs,Rachel A. Freedman,Charles S. Kuzma,Jeffrey J. Kirshner,Deborah Schrag +25 more
TL;DR: Participants in multicenter cancer trials are willing and able to report their own symptomatic AEs at most clinic visits and report more AEs than investigators, which may improve the precision of AE reporting in cancer trials.
Journal ArticleDOI
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Maura N. Dickler,William T. Barry,Constance Cirrincione,Matthew J. Ellis,Mary Ellen Moynahan,Federico Innocenti,Arti Hurria,Hope S. Rugo,Diana Lake,Olwen Hahn,Bryan P. Schneider,Debasish Tripathy,Lisa A. Carey,Eric P. Winer,Clifford A. Hudis +14 more
TL;DR: The addition of bevacizumab to letrozole improved PFS in hormone receptor-positive MBC, but this benefit was associated with a markedly increased risk of grade 3 to 4 toxicities.
Journal ArticleDOI
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Komal Jhaveri,Sarat Chandarlapaty,Sarat Chandarlapaty,Diana Lake,Diana Lake,Teresa Gilewski,Teresa Gilewski,Mark E. Robson,Mark E. Robson,Shari Goldfarb,Shari Goldfarb,Pamela Drullinsky,Steven Sugarman,Steven Sugarman,Carolyn Wasserheit-Leiblich,Carolyn Wasserheit-Leiblich,Julie Fasano,Mary Ellen Moynahan,Mary Ellen Moynahan,Gabriella D'Andrea,Gabriella D'Andrea,Kristina Lim,Laura Reddington,Sofia Haque,Sujata Patil,Lynne Bauman,V. Vukovic,Iman El-Hariry,Clifford A. Hudis,Clifford A. Hudis,Shanu Modi,Shanu Modi +31 more
TL;DR: Ganetespib was well tolerated and responses in more targeted populations harboring specific HSP90-dependent oncoproteins justifies its further study, particularly as part of rational combinations.